SAN CARLOS, Calif., July 21, 2023 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. IOVA, a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that on July 20, 2023 (the “Date of Grant”), the Company approved the grant of…Read More
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635c4 Iovance Biotherapeutics NASDAQIOVA
